KZIA (Kazia Therapeutics) Net Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KZIA Kazia Therapeutics Ltd KZIA
33 GF Score
Price $12.00
! 5 Warning Signs
View Full Analysis

What is Kazia Therapeutics Net Margin %?

Kazia Therapeutics KZIA -2.60% 33 Net Margin % is 0.00% as of Dec. 2025. GuruFocus rates KZIA with a GF Score™ of 33/100. The stock has 5 warning signs investors should review. Among 948 Biotechnology companies, Kazia Therapeutics ranks worse than 97.26% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Kazia Therapeutics's Net Income for the six months ended in Dec. 2025 was $-8.34 Mil. Kazia Therapeutics's Revenue for the six months ended in Dec. 2025 was $0.00 Mil. Therefore, Kazia Therapeutics's net margin for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Kazia Therapeutics's Net Margin % or its related term are showing as below:

KZIA' s Net Margin % Range Over the Past 10 Years
Min: -55600   Med: -3123.2   Max: -55.45
Current: -55600

KZIA's Net Margin % is ranked worse than
97.26% of 948 companies
in the Biotechnology industry
Industry Median: -75.55 vs KZIA: -55600.00

Kazia Therapeutics  (NAS:KZIA) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Kazia Therapeutics Net Margin % Related Terms

Kazia Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Kazia Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kazia Therapeutics Net Margin % Chart

Kazia Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -55.45 0.00 0.00 -1,159.88 -49,918.52

Kazia Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -777.69 0.00 -24,711.11 0.00

KZIA vs OKUR, TNYA, OTLK: Net Margin % Comparison

For the Biotechnology subindustry, Kazia Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kazia Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Kazia Therapeutics's Net Margin % falls into.


KZIA
33GF Score
Kazia Therapeutics Ltd KZIA
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kazia Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Kazia Therapeutics's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-13.478/0.027
=-49,918.52 %

Kazia Therapeutics's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-8.34/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Kazia Therapeutics (KZIA) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Kazia Therapeutics and its competitors. According to the industry distribution chart, Kazia Therapeutics ranks #922 out of 948 companies in the Biotechnology industry, placing it in the top 97.3%.
Is Kazia Therapeutics' Net Margin % too high?
Kazia Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Kazia Therapeutics ranks #922 out of 948 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kazia Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Kazia Therapeutics' Net Margin % compare to OKUR and TNYA?
According to the Biotechnology industry distribution chart, Kazia Therapeutics ranks #922 out of 948 companies for Net Margin %. This places Kazia Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Kazia Therapeutics and its competitors. Kazia Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kazia Therapeutics stock overvalued right now?
Kazia Therapeutics (KZIA) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Kazia Therapeutics' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Kazia Therapeutics (KZIA), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kazia Therapeutics Business Description

Address 300 Barangaroo Avenue, Level 24, Three International Towers, Sydney, NSW, AUS, 2000
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
33GF Score

Get the complete analysis for KZIA

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.00
Price